Target Laboratories touts phase II study results

By staff writers

October 16, 2019 -- Imaging contrast agent developer Target Laboratories said that its OTL38 intraoperative cancer imaging agent was found to be safe and efficacious for detecting ovarian cancer tumors in a phase II multicenter study.

In the study, a research team led by Dr. Leslie Randall of the University of California, Irvine reported that OTL38's near-infrared imaging helped surgeons to detect additional lesions in 48.3% of the patients compared with traditional detection techniques. It also yielded 97% sensitivity when controlling for detection correlation of multiple lesions within a single patient, according to the firm.

The research was published in the October issue of Gynecologic Oncology.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking